Safety of Quadrivalent Meningococcal Conjugate Vaccine in Children 2-10 Years
- PMID: 28719502
- DOI: 10.1097/INF.0000000000001696
Safety of Quadrivalent Meningococcal Conjugate Vaccine in Children 2-10 Years
Abstract
Background: Quadrivalent meningococcal conjugate vaccine is recommended for children, adolescents and adults at increased risk of meningococcal disease. In 2011, MenACWY-CRM (Menveo, GSK, Siena, Italy) was approved for children 2-10 years of age in the United States. Although no safety concerns arose from clinical trials, it remains important to monitor its safety in routine clinical settings.
Methods: Kaiser Permanente Southern California members 2-10 years old who received MenACWY-CRM between September 2011 and September 2014 were included. Electronic health records were searched using a validated algorithm to identify 26 prespecified events of interests (EOIs) and serious medically attended events (SMAEs) from inpatient or emergency settings up to 1 year after MenACWY-CRM vaccination. SMAEs were categorized by International Classification of Diseases, 9th revision diagnostic categories. All events were reviewed to confirm the diagnosis and symptom onset date. The study was descriptive (NCT01452438); no statistical tests were performed.
Results: Among 387 vaccinated children, 327 with ≥6 months membership before vaccination were analyzed. Among EOIs, 9 asthma cases and 1 myasthenia gravis case underwent chart review which confirmed 1 incident asthma case occurring 237 days after concomitant vaccination with MenACWY-CRM and typhoid vaccine. Thirty-one children experienced SMAEs, most commonly because of unrelated injury and poisoning. The remaining events occurred sporadically after vaccination and most were unlikely related to vaccination based on medical record review.
Conclusions: One incident EOI of asthma late in the 1-year observation period and sporadic distribution of SMAEs were observed. These data do not suggest safety concerns associated with MenACWY-CRM vaccination in children 2-10 years old.
Similar articles
-
Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.Vaccine. 2014 Feb 12;32(8):965-72. doi: 10.1016/j.vaccine.2013.12.034. Epub 2014 Jan 4. Vaccine. 2014. PMID: 24397906 Clinical Trial.
-
Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds.Pediatrics. 2017 Jan;139(1):e20162084. doi: 10.1542/peds.2016-2084. Pediatrics. 2017. PMID: 28025240
-
Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.J Pediatr. 2014 Jun;164(6):1409-15.e4. doi: 10.1016/j.jpeds.2014.02.025. Epub 2014 Mar 20. J Pediatr. 2014. PMID: 24657122 Clinical Trial.
-
Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.Expert Rev Vaccines. 2011 Jan;10(1):21-33. doi: 10.1586/erv.10.147. Expert Rev Vaccines. 2011. PMID: 21162617 Review.
-
Use of MenACWY-CRM in adolescents in the United States.J Adolesc Health. 2013 Mar;52(3):271-7. doi: 10.1016/j.jadohealth.2012.07.017. Epub 2012 Sep 25. J Adolesc Health. 2013. PMID: 23299001 Review.
Cited by
-
Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.Hum Vaccin Immunother. 2022 Nov 30;18(6):2099142. doi: 10.1080/21645515.2022.2099142. Epub 2022 Aug 10. Hum Vaccin Immunother. 2022. PMID: 35947774 Free PMC article.
-
Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.J Neurol. 2022 Aug;269(8):3965-3981. doi: 10.1007/s00415-022-11140-9. Epub 2022 May 3. J Neurol. 2022. PMID: 35503373 Free PMC article. Review.
-
A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.Infect Dis Ther. 2022 Apr;11(2):639-655. doi: 10.1007/s40121-021-00519-2. Infect Dis Ther. 2022. PMID: 34591258 Free PMC article. Review.
-
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR Recomm Rep. 2020 Sep 25;69(9):1-41. doi: 10.15585/mmwr.rr6909a1. MMWR Recomm Rep. 2020. PMID: 33417592 Free PMC article.
-
Real-world evidence of quadrivalent meningococcal conjugate vaccine safety in the United States: a systematic review.Hum Vaccin Immunother. 2021 May 4;17(5):1432-1441. doi: 10.1080/21645515.2020.1829412. Epub 2020 Dec 17. Hum Vaccin Immunother. 2021. PMID: 33327853 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources